BioMimetic's Augment Bone Graft Goes To Panel In May
This article was originally published in The Gray Sheet
Executive Summary
FDA's Orthopedic and Rehabilitation Devices panel will meet May 12 to discuss a pre-market approval application for BioMimetic Therapeutics’ Augment fully synthetic bone graft, the firm announced Jan. 31.
You may also be interested in...
BioMimetic Augment PMA Delayed Slightly As FDA Seeks Additional Data
FDA approval of BioMimetic Therapeutics' Augment synthetic bone graft will likely be delayed by several months after the agency recently requested 12-month follow-up data, the firm said
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.